RecruitingPhase 2NCT05653193

Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study

Studying Aspergillosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Manchester University NHS Foundation Trust
Principal Investigator
Chris Kosmidis, MD
Manchester University NHS Foundation Trust
Intervention
Interferon Gamma-1B 0.1 MG Per 0.5 ML Injection PLUS antifungals as standard of care(drug)
Enrollment
50 enrolled
Eligibility
18 years · All sexes
Timeline
2024 – 2026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05653193 on ClinicalTrials.gov

Other trials for Aspergillosis

Additional recruiting or active studies for the same condition.

See all trials for Aspergillosis →

← Back to all trials